COSCIENS Biopharma Inc., formerly Aeterna Zentaris Inc., is a specialty biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of pharmaceutical and diagnostic products, including those focused on areas of unmet medical need. Its lead product, macimorelin (Macrilen; Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The Company is also engaged in the development of therapeutic assets and proprietary extraction technology, which is applied to the production of active ingredients from renewable plant resources used in cosmeceutical products (i.e., oat beta glucan and avenanthramides, which are found in skincare product brands like Aveeno and Burtâs Bees formulations) and being developed as potential nutraceuticals and/or pharmaceuticals.
äŒæ¥ã³ãŒãCSCI
äŒç€ŸåCOSCIENS Biopharma Inc
äžå Žæ¥Dec 19, 1995
æé«çµå¶è²¬ä»»è
ãCEOãMs. Anna Biehn
åŸæ¥å¡æ°- -
蚌åžçš®é¡Ordinary Share
æ±ºç®ææ«Dec 19
æ¬ç€Ÿæåšå°C/O Norton Rose Fulbright Canada Llp
éœåžTORONTO
蚌åžååŒæThe Toronto Stock Exchange
åœCanada
éµäŸ¿çªå·M5K 1E7
é»è©±çªå·18439003201
ãŠã§ããµã€ãhttps://www.cosciensbio.com/
äŒæ¥ã³ãŒãCSCI
äžå Žæ¥Dec 19, 1995
æé«çµå¶è²¬ä»»è
ãCEOãMs. Anna Biehn
éå»5幎éã®é
åœéç·æ¯æé¡ã¯
0.00
ç±³ãã«ã§ããã

ããŒã¿ãªã